Articaine Hydrochloride Market

Global Articaine Hydrochloride Market Size (2024 to 2029)

The size of the global articaine hydrochloride market was worth USD 1.37 billion in 2023. The global market is expected to reach USD 2.06 billion by 2029 from USD 1.47 billion in 2024, growing at a CAGR of 7.07% from 2024 to 2029.

Articaine hydrochloride is a local anesthetic used to control pain by blocking nerve signals in the body. Articaine is a form of local anaesthetic amide that is useful in dentistry. Articaine Hydrochloride is indicated for local, infiltrative, or conductive anesthesia in simple and complex dental procedures in adults and pediatric patients four years of age and older, making it a good choice for anesthesia. Articaine works as a better alternative to perform more efficient procedures and enable better clinical care.

Current Scenario of the Global Articaine Hydrochloride Market

Articaine hydrochloride is the most popular anesthetic option across developed countries such as Germany, Italy, the USA, and Australia, among others, where it is used by approximately 97.5% of dentists. The market is also expected to be driven by the increased number of global dental surgeries. Periodontal disease is one of the major dental diseases affecting human populations worldwide, with high prevalence rates and surgical procedures. In Italy, the prevalence of periodontal disease will increase over time. In 2019, about 15.88 thousand Italians per 100,000. According to the CDC, the prevalence of periodontitis was 70.98% to 87.42% in the German population, with a significantly higher prevalence in men. According to the FDI World Dental Federation, more than 80.23% of people in Asia-Pacific, including India, Bangladesh, Nepal, Malaysia, and Indonesia, suffer from poor oral hygiene. Additionally, between 40.65% and 59.5% of the population in China and Australia suffer from dental disorders. As per the FDI World Dental Federation report, more than 80% of people suffer from dental caries; such countries are the Asia Pacific, containing countries like Malaysia, Nepal, Indonesia, Bangladesh, and India. Besides, 40 to 59% of the population in China and Australia suffer from dental caries. Successful research and development backed by clinical trials and advancements in dental anesthesia system devices will provide significant growth opportunities for the market. Additionally, increased use of articaine for dental surgeries and rising expenditure on dental treatments drive market growth.

MARKET DRIVERS

The growing population suffering from dental caries and other periodontal diseases worldwide is propelling the articaine hydrochloride market growth.

Articaine hydrochloride is the most popular local anesthetic in dentistry. The advancement of the dental anesthesia delivery system device and the innovative nature of the dental anesthesia industry propel the growth of the articaine hydrochloride market. Periodontal disease is one of the foremost dental conditions influencing human populations worldwide with high prevalence rates. Periodontal disease is more common in the Asia-Pacific. The growing awareness of preventive and corrective treatments is also one of the growth factors of this market. The articaine hydrochloride market is a new management system encouraging dental specialists to manage more effective practices and focus on better clinical care. 

The rising focus on oral hygiene and rising awareness of aesthetic, preventive, and corrective treatments across the globe are further boosting the global articaine hydrochloride market growth.

According to the Centers for Disease Control and Prevention (CDC), 13.2% of children aged 5 to 19 and 25.9% of adults aged 20 to 44 had untreated tooth decay between 2015 and 2018, and 85.9% of children aged 2 to 17 had a dental visit in 2018. Additionally, in 2019, 64.9% of adults aged 18 and older had a dental visit. According to the WHO, it is estimated that approximately 2.37 billion people suffer from dental caries that affect their permanent teeth. Furthermore, a recent publication reported that nearly 90% of Chinese adults suffered from periodontal disease of varying severity, of which more than 30% had severe periodontitis, including 43.55% in the age group of 65-74 years old.  Hence, the rising number of dental caries drives the demand for articaine hydrochloride.

The prevalence of periodontal diseases is estimated to be 20 to 50% worldwide. In 2010, the global productivity loss due to severe periodontitis was estimated at US$54 billion per year. Furthermore, the prevalence of the periodontal disease will increase in the coming years due to the increased retention of natural teeth due to a significant reduction in tooth loss among the elderly population. All these factors will significantly impact the studied market during the forecast period.

MARKET RESTRAINTS

High dental procedure costs and unfavorable reimbursement policies are expected to hamper the market growth.

For instance, more than 90% of dental costs are out-of-pocket expenses for much of the population in APAC due to the lack of proper reimbursement policies, which will make it difficult for people to have dental care procedures. In addition, some popular local anesthetics other than articaine are prilocaine, lidocaine, mepivacaine, and bupivacaine, and their availability and use as alternative products are likely to hinder the market growth. In addition, prices are not regulated with side effects, insufficient drug knowledge regarding the use of articaine hydrochloride, and the presence of significant and excessive expansion of pharmaceutical companies hampers the market expansion. The presence of a vast production capacity exerted pressure on prices. Generics have captured most of the market, and counterfeit products have limited market growth.

Impact of COVID-19 on the global articaine hydrochloride market

The COVID-19 pandemic has tremendously impacted the healthcare infrastructure with a growing focus on treating those suffering from COVID-19. This reduced the number of dental clinic visits and the postponement of non-essential procedures, limiting the risk of transmitting the virus. Unfortunately, this has dramatically decreased the sales in the articaine hydrochloride market, with a sharp drop in drug production due to lockdown and trade restrictions across the globe.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Articaine Hydrochloride Market Analysis By Application

Throughout the forecast period, the nerve block segment is estimated to be the fastest-growing segment of the articaine hydrochloride market. It is projected to grow at a healthy CAGR during the forecast period. A nerve block is the preferred mode of anesthesia for the dentist's removal of wisdom teeth and other dental procedures.

Global Articaine Hydrochloride Market Analysis By End-User

In 2023, the dental clinics segment accounted for the most significant share of the global articaine hydrochloride market. This segment is expected to experience a healthy growth rate during the forecast period owing to the increasing number of dental clinics across the globe and preferred places by patients for treatment.

REGIONAL ANALYSIS

In 2023, Europe accounted for the largest share of the global articaine hydrochloride market, followed by North America and the Asia Pacific. However, Asia Pacific is to witness the highest CAGR in the coming years. The European market growth can be attributed to dentists' increased use of articaine hydrochloride, the growing number of dental clinics, and the high incidence of dental caries. Italy and France are the high-revenue generating markets in the European region. According to the International Classification of Periodontal Diseases, approximately 52% of adults in France suffer from periodontal problems.

North America held a substantial share in the global market in 2023 and is expected to register notable growth during the forecast period due to high healthcare expenditures, well-developed medical facilities, and favorable reimbursement policies for dental care. Other fundamental factors contributing to the expansion of the market include increasing incidence of dental caries, periodontics, and oral cancer in the region, high rate of cosmetic surgeries, increase in soft tissue, and laser surgeries are driving the market. According to the CDC, in 2020, nearly half of 46% of adults over 30 had signs of periodontal disease. In addition, periodontal disease affected about 9% of adults in 2020.

Asia-Pacific is expected to account for the highest market growth in the coming years. China is the largest producer of articaine hydrochloride and will dominate the regional market due to successful production and distribution to meet unmet market demand. In addition, countries like Australia, China, Japan, and India will grow due to the high adoption of new technologies, their use of dental applications, and the rapid growth in the geriatric population. According to a 2018 United Nations Population Fund statistical report, people aged 60 and over made up about 13.9% of the world's population that year. This figure would increase by around 22% by 2050.

KEY PLAYERS IN THE GLOBAL ARTICAINE HYDROCHLORIDE MARKET

Some of the prominent companies operating in the global articaine hydrochloride market profiled in the report are 3M, Anhui BBCA Pharmaceutical Co., Ltd., Dentsply Sirona, Inibsa Dental S.L.U., Jinan Chenghui Shuangda Chemical Co., Ltd, Jinan Ruixing Pharmaceutical Technology Co., Ltd, Manus Aktteva Biopharma LLP, Pfizer Inc., Pierrel S.p.A., Sanofi, Septodont, Siegfried AG and Sigma Aldrich.

RECENT HAPPENINGS IN THE MARKET

• In March 2018, Dentsply Sirona announced a definitive agreement to acquire OraMetrix, one of the leading providers of innovative 3D technology solutions that improve the quality and efficiency of orthodontic care. The acquisition, combined with GAC's media expertise and digital technologies from Dentsply Sirona, will enable Dentsply Sirona to provide a comprehensive orthodontic offering that will include a clear arch-to-arch solution.
• In June 2016, PierrelS.p.A. Signed a ten-year agreement with Safco Dental Supply Co. to produce and market anesthetic articaine in the United States.
• In February 2016, Septodont announced its acquisition of DLA, a factory for injectable dental anesthetics manufactured in Brazil. In addition, Septodont announced today that it had acquired the injectable dental anesthetics manufacturing plant of Dentsply International. The plant is in Catanduva, São Paulo, Brazil, and through Septodont's Brazilian subsidiary, TDV.

DETAILED SEGMENTATION OF THE GLOBAL ARTICAINE HYDROCHLORIDE MARKET INCLUDED IN THIS REPORT

This research report on the global articaine hydrochloride market has been segmented and sub-segmented based on application, end-user, and region.

By Application

• Infiltration               
• Nerve Block            

By End User

• Dental Clinics          
• Hospitals  
• Academic and Research Institutes

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa